Mankind Pharma Ltd.
NSE: MANKIND · Pharmaceuticals
Snapshot
Unlock Mankind Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mankind Pharma Limited is a pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical formulations and consumer healthcare products. Its portfolio spans acute and chronic therapeutic areas, alongside well-known consumer brands such as Manforce and Prega News.
Business Model
The company generates revenue through the domestic and international sale of pharmaceutical drugs and consumer healthcare products. It also diversifies its income streams through the manufacturing of packing materials, ayurvedic products, and ancillary services including real estate and IT.
- Founded:1986
Growth Outlook
Growth is driven by the expansion of its chronic and acute therapeutic pharmaceutical segments and the continued market penetration of its established consumer healthcare brands. The company also leverages its manufacturing capabilities to support both internal product lines and external trading activities.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent government regulations and price controls that can impact profit margins.
- Competitive Market. The company faces intense competition from both domestic and multinational pharmaceutical firms in the Indian market.
- Supply Chain Dependency. Reliance on external suppliers for raw materials and bulk drugs poses a risk to production continuity and cost stability.
- Product Liability. As a manufacturer of healthcare and pharmaceutical products, the company is exposed to potential legal risks and reputational damage from product quality issues.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Mankind Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹14,278 Cr
TTM · consolidated
NET PROFIT
₹1,938 Cr
TTM · consolidated
EPS
₹46.35
TTM · consolidated
RETURN ON EQUITY
13.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.5%
TTM · consolidated
P/E
54.9x
Q4 FY26 · consolidated
EV/EBITDA
27.9x
Q4 FY26 · consolidated
EBITDA MARGIN
27.8%
TTM · consolidated
NET PROFIT MARGIN
16.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4%
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Mankind Pharma Ltd.MANKIND | 81,112 | 54.93 | 27.93 | 16.3% | 27.8% | 13.1% | 13.5% | -3.0% |
Cipla Ltd.CIPLA | 99,316 | 29.76 | 16.96 | 2.2% | 24.0% | 12.1% | 16.1% | -3.1% |
Zydus Lifesciences Ltd.ZYDUSLIFE | 89,212 | 23.03 | 14.03 | 16.8% | 33.1% | 20.7% | 23.3% | +19.1% |
Aurobindo Pharma Ltd.AUROPHARMA | 74,365 | 25.66 | 12.21 | 6.1% | 21.8% | 10.3% | 15.1% | +34.3% |
Alkem Laboratories Ltd.ALKEM | 63,210 | 29.66 | 19.40 | 13.5% | 24.4% | 18.9% | 21.2% | +14.1% |
Biocon Ltd.BIOCON | 59,592 | 157.96 | 19.22 | 10.9% | 22.3% | 1.5% | 3.1% | +11.7% |
As of Q4 FY26
Financials
Mankind Pharma Ltd.
NSE: MANKIND · Pharmaceuticals
Snapshot
Unlock Mankind Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mankind Pharma Limited is a pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical formulations and consumer healthcare products. Its portfolio spans acute and chronic therapeutic areas, alongside well-known consumer brands such as Manforce and Prega News.
Business Model
The company generates revenue through the domestic and international sale of pharmaceutical drugs and consumer healthcare products. It also diversifies its income streams through the manufacturing of packing materials, ayurvedic products, and ancillary services including real estate and IT.
- Founded:1986
Growth Outlook
Growth is driven by the expansion of its chronic and acute therapeutic pharmaceutical segments and the continued market penetration of its established consumer healthcare brands. The company also leverages its manufacturing capabilities to support both internal product lines and external trading activities.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent government regulations and price controls that can impact profit margins.
- Competitive Market. The company faces intense competition from both domestic and multinational pharmaceutical firms in the Indian market.
- Supply Chain Dependency. Reliance on external suppliers for raw materials and bulk drugs poses a risk to production continuity and cost stability.
- Product Liability. As a manufacturer of healthcare and pharmaceutical products, the company is exposed to potential legal risks and reputational damage from product quality issues.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Mankind Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹14,278 Cr
TTM · consolidated
NET PROFIT
₹1,938 Cr
TTM · consolidated
EPS
₹46.35
TTM · consolidated
RETURN ON EQUITY
13.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.5%
TTM · consolidated
P/E
54.9x
Q4 FY26 · consolidated
EV/EBITDA
27.9x
Q4 FY26 · consolidated
EBITDA MARGIN
27.8%
TTM · consolidated
NET PROFIT MARGIN
16.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4%
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26